Relay Therapeutics, Inc. (RLAY) Stock Grade

About Relay Therapeutics, Inc.'s fundamentals

Relay Therapeutics is a biotechnology company with a market capitalization of $1.5 billion that is experiencing strong revenue growth at 53.4% year-over-year, indicating expanding business activity. However, the company is currently unprofitable, with a net margin of -1800.6% and a reported net loss in its latest annual statement, which is typical for early-stage biotech firms investing heavily in research and development. The company does not pay a dividend, and profitability metrics like price-to-earnings ratio and return on equity are not meaningful given the current loss position.